Показано 0 из 0
Дата |
---|
19:00 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
19.04.2024 |
18.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
|
|
0.133
|
0.133
|
0.133
|
0.133
|
|
|
|
|
0.1345
|
0.205
|
0.1335
|
0.1335
|
0.1445
|
0.1445
|
|
|
|
|
|
|
0.1325
|
0.1325
|
0.138
|
0.138
|
|
|
|
|
0.1445
|
0.1925
|
0.133
|
0.121
|
0.133
|
0.121
|
|
|
|
|
0.154
|
0.203
|
0.1005
|
0.0964
|
0.1005
|
0.0964
|
|
|
|
|
0.1245
|
0.171
|
0.0902
|
0.0902
|
0.0902
|
0.0902
|
|
|
|
|
0.115
|
0.1605
|
0.0942
|
0.0942
|
0.0942
|
0.0942
|
|
|
|
|
0.1185
|
0.1645
|
0.099
|
0.099
|
0.099
|
0.099
|
|
|
|
|
0.123
|
0.169
|
0.101
|
0.101
|
0.101
|
0.101
|
|
|
|
|
0.1255
|
0.172
|
0.1095
|
0.105
|
0.1095
|
0.105
|
|
|
|
|
Gabather AB is engaged in developing novel drugs to treat several diseases originating in the central nervous system. It has four main focus areas anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including for Alzheimer's disease.